Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Bought by CIBC Asset Management Inc

CIBC Asset Management Inc grew its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 14.5% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 5,134 shares of the biopharmaceutical company’s stock after acquiring an additional 651 shares during the period. CIBC Asset Management Inc’s holdings in Alnylam Pharmaceuticals were worth $1,208,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of ALNY. Huntington National Bank lifted its position in shares of Alnylam Pharmaceuticals by 91.8% during the 3rd quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 45 shares during the last quarter. Hollencrest Capital Management acquired a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at $29,000. R Squared Ltd acquired a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter valued at $33,000. Washington Trust Advisors Inc. acquired a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at $42,000. Finally, True Wealth Design LLC lifted its position in shares of Alnylam Pharmaceuticals by 15,300.0% during the 3rd quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company’s stock valued at $42,000 after acquiring an additional 153 shares during the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Trading Down 0.2 %

Alnylam Pharmaceuticals stock opened at $250.59 on Friday. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71. The company has a market capitalization of $32.44 billion, a price-to-earnings ratio of -115.48 and a beta of 0.35. Alnylam Pharmaceuticals, Inc. has a one year low of $141.98 and a one year high of $304.39. The company’s fifty day moving average price is $254.14 and its two-hundred day moving average price is $263.03.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.03). On average, analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, EVP Tolga Tanguler sold 1,469 shares of the company’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $368,689.62. Following the completion of the sale, the executive vice president now directly owns 13,191 shares in the company, valued at $3,310,677.18. This represents a 10.02 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CMO Pushkal Garg sold 52,592 shares of the company’s stock in a transaction dated Monday, January 27th. The shares were sold at an average price of $285.00, for a total transaction of $14,988,720.00. Following the sale, the chief marketing officer now owns 11,989 shares of the company’s stock, valued at $3,416,865. This trade represents a 81.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 81,356 shares of company stock valued at $22,498,551 over the last three months. 1.50% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the company. Scotiabank cut their price objective on Alnylam Pharmaceuticals from $310.00 to $300.00 and set a “sector outperform” rating for the company in a research report on Friday, February 14th. Royal Bank of Canada restated an “outperform” rating and issued a $300.00 target price on shares of Alnylam Pharmaceuticals in a report on Tuesday, February 11th. Raymond James increased their target price on Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the company an “outperform” rating in a report on Friday, November 1st. Canaccord Genuity Group increased their target price on Alnylam Pharmaceuticals from $384.00 to $385.00 and gave the company a “buy” rating in a report on Tuesday, February 18th. Finally, Sanford C. Bernstein reduced their target price on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating for the company in a report on Tuesday, January 7th. One analyst has rated the stock with a sell rating, six have given a hold rating and nineteen have issued a buy rating to the stock. According to data from MarketBeat, Alnylam Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $299.48.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.